Antineoplastic Agents
/ therapeutic use
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Asparaginase
/ therapeutic use
Child
Consolidation Chemotherapy
Female
Humans
Male
Mercaptopurine
/ therapeutic use
Methotrexate
/ therapeutic use
Methyltransferases
/ genetics
Neoplasm, Residual
Polymorphism, Genetic
Precursor Cell Lymphoblastic Leukemia-Lymphoma
/ drug therapy
Vincristine
/ therapeutic use
6-mercaptopurine
Childhood acute lymphoblastic leukemia
minimal residual disease
thiopurine methyltransferase
Journal
Pediatric hematology and oncology
ISSN: 1521-0669
Titre abrégé: Pediatr Hematol Oncol
Pays: England
ID NLM: 8700164
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
pubmed:
19
11
2020
medline:
12
6
2021
entrez:
18
11
2020
Statut:
ppublish
Résumé
Bone marrow minimal residual disease (MRD) is the strongest predictor of relapse in children with acute lymphoblastic leukemia (ALL). 6-mercaptopurine (6MP) in ALL therapy has wide inter-individual variation in disposition and is strongly influenced by polymorphisms in the thiopurine methyltransferase (
Identifiants
pubmed: 33205673
doi: 10.1080/08880018.2020.1842570
doi:
Substances chimiques
Antineoplastic Agents
0
Vincristine
5J49Q6B70F
Mercaptopurine
E7WED276I5
Methyltransferases
EC 2.1.1.-
thiopurine methyltransferase
EC 2.1.1.67
Asparaginase
EC 3.5.1.1
Methotrexate
YL5FZ2Y5U1
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM